25C-NBOMe (NBOMe-2C-C)

Overview

25C-NBOMe is a synthetic psychedelic of the phenethylamine class and the N-benzyl derivative of 2C-C. It belongs to the NBOMe series, a family of ultra-potent compounds developed in the 2000s as ligands for mapping serotonin receptors in the brain. 25C-NBOMe gained notoriety in the 2010s as a substance associated with severe adverse events and fatalities, and is now a controlled substance in most jurisdictions.

IUPAC name: 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
Molecular formula: C₁₈H₂₂ClNO₃
Molecular weight: ~335.83 g/mol
CAS Number: 1227608-02-7
Class: Psychedelic phenethylamine (N-benzyl substituted); potent 5-HT₂A agonist

History & Origin

25C-NBOMe was developed in the 2000s by chemist Ralf Heim at the Free University of Berlin as part of a research program synthesizing high-affinity 5-HT₂A ligands for positron emission tomography (PET) imaging studies. It was never intended for human consumption. Beginning around 2010, it began appearing on the recreational drug market, often sold on blotter paper misrepresented as LSD.

Pharmacology

25C-NBOMe is an extremely potent 5-HT₂A receptor agonist. The N-benzyl substitution dramatically increases potency compared to the parent compound 2C-C, but also narrows the safety margin.

Receptor binding: Potent full agonist at 5-HT₂A; agonist at 5-HT₂B and 5-HT₂C
Active oral dose: ~500–1500 µg (micrograms)
Onset: 15–45 minutes (sublingual/buccal)
Duration: 6–10 hours
Route: Almost exclusively sublingual or buccal (insufflation and vaporization reported but riskier)

Documented Effects

Reported effects at common doses include:

Visual distortions, geometric patterns, color enhancement
Strong euphoria and empathogenic feelings
Time dilation
Synesthesia
Stimulation and increased heart rate

At higher doses:

Severe anxiety, panic, paranoia
Confusion and dissociation
Nausea and vasoconstriction
Seizures, hyperthermia, serotonin syndrome, and death have been reported

Safety & Harm Considerations

25C-NBOMe carries a substantially worse safety profile than classic psychedelics:

Narrow safety margin — the difference between an active dose and a dose associated with severe toxicity or death is small.
Multiple confirmed fatalities — clinical case reports link 25C-NBOMe (and the broader NBOMe series) to deaths from seizures, respiratory arrest, serotonin syndrome, and traumatic injury during dissociative states.
Often misrepresented as LSD — blotter sold as “LSD” has frequently been found to contain 25C-NBOMe or other NBOMes, leading to unexpected, intense experiences.
Vasoconstriction — peripheral vasoconstriction with risk of tissue ischemia has been reported.
Serotonergic interactions — dangerous with SSRIs, MAOIs, tramadol, and other serotonergic substances.
No known treatment — there is no specific antidote; management is supportive.

Legality

United States: Schedule I controlled substance (placed in 2015 along with other NBOMe compounds).
United Kingdom: Class A (Temporary Class Drug Order, then permanent).
Canada: Schedule I.
Australia: Schedule 9.
Germany / EU: Controlled under narcotic laws; covered by the European generic definitions in many states.
China: Controlled since 2015.

It is illegal to possess, sell, or manufacture in essentially all major jurisdictions.